GeneMind Biosciences Co., Ltd., Shenzhen 518000, China.
Genomics Proteomics Bioinformatics. 2024 May 9;22(1). doi: 10.1093/gpbjnl/qzae006.
DNA sequencers have become increasingly important research and diagnostic tools over the past 20 years. In this study, we developed a single-molecule desktop sequencer, GenoCare 1600 (GenoCare), which utilizes amplification-free library preparation and two-color sequencing-by-synthesis chemistry, making it more user-friendly compared with previous single-molecule sequencing platforms for clinical use. Using the GenoCare platform, we sequenced an Escherichia coli standard sample and achieved a consensus accuracy exceeding 99.99%. We also evaluated the sequencing performance of this platform in microbial mixtures and coronavirus disease 2019 (COVID-19) samples from throat swabs. Our findings indicate that the GenoCare platform allows for microbial quantitation, sensitive identification of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and accurate detection of virus mutations, as confirmed by Sanger sequencing, demonstrating its remarkable potential in clinical application.
在过去的 20 年中,DNA 测序仪已成为越来越重要的研究和诊断工具。在这项研究中,我们开发了一种单分子桌面测序仪,GenoCare 1600(GenoCare),它利用无扩增文库制备和双色合成测序化学,与以前用于临床的单分子测序平台相比,更具用户友好性。使用 GenoCare 平台,我们对大肠杆菌标准样本进行了测序,准确率超过 99.99%。我们还评估了该平台在微生物混合物和来自咽喉拭子的 2019 年冠状病毒病(COVID-19)样本中的测序性能。我们的研究结果表明,GenoCare 平台可进行微生物定量,灵敏地鉴定严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)病毒,并通过 Sanger 测序准确检测病毒突变,这表明其在临床应用中具有巨大潜力。